Detalles de la búsqueda
1.
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21266704
2.
Poor sensitivity of iPSC-derived neural progenitors and glutamatergic neurons to SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-501370
3.
A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21262027
4.
Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-193672
5.
Robust and Functional Immunity up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-455901
6.
B.1.1.7 and B.1.351 SARS-CoV-2 variants display enhanced Spike-mediated fusion
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-448011
7.
Syncytia formation by SARS-CoV-2 infected cells
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-202028
8.
The spike-stabilizing D614G mutation interacts with S1/S2 cleavage site mutations to promote the infectious potential of SARS-CoV-2 variants
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-492832
9.
Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without Omicron breakthrough infection.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-22277885
10.
SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-20140178
11.
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-462234
12.
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-445838
13.
Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised Patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261766
14.
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21261769
15.
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants.
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21257393
16.
Evolution of human antibody responses up to one year after SARS-CoV-2 infection
Preprint
en Inglés
| PREPRINT-MEDRXIV | ID: ppmedrxiv-21256823
17.
Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-442916
18.
Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-436648
19.
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-430472
20.
SARS-CoV-2 infection damages airway motile cilia and impairs mucociliary clearance
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-328369